ArticleAACE endocrinology and diabetes
Isolated β-Human Chorionic Gonadotropin Elevation-From Pregnancy to Fragile X-associated Premature Ovarian Insufficiency.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Elevated β-human chorionic gonadotropin (β-HCG) in a young female usually suggests pregnancy, gestational trophoblastic disease or germ cell tumor. We describe β-HCG elevation in a young female using intrauterine device (IUD), ultimately diagnosed with Fragile X-associated premature ovarian insufficiency (FXPOI). Case Report: A 31-year-old woman with Hashimoto's hypothyroidism and a levonorgesterel IUD presented to the emergency room for hematemesis. She had a positive urine and serum pregnancy test. Ultrasound showed no evidence of intrauterine gestation with a normally centered IUD. After removal of the IUD and methotrexate therapy for presumed ectopic pregnancy in an unknown location, β-HCG level remained elevated. Heterophile antibody interference was ruled out. Over the next 2 months, further testing confirmed FXPOI (follicle-stimulating hormone 174.58 mIU/mL, luteinizing hormone 70.61 mIU/mL, undetectable estradiol, undetectable progesterone, undetectable anti-mullerian hormone, and one FMR1 premutation allele). Hormone therapy with oral estradiol 2 mg daily and cyclic oral micronized progesterone 200 mg on 12 days of each month was initiated. Discussion: In menopause, decreased estradiol and progesterone lead to mildly elevated β-HCG through luteinizing hormone-mediated β-HCG production in the pituitary gland. This may be confused with pregnancy and could delay diagnosis of premature menopause due to premature ovarian insufficiency (POI), especially in young females. In young patients with normal karyotype, Fragile X premutation is the most common genetic cause of POI. Conclusion: After pregnancy has been ruled out, less common causes of β-HCG elevations like gestational trophoblastic disease, germ cell tumors, POI associated menopause, and heterophile antibody interference, should be evaluated. FXPOI should be considered in young patients with β-HCG elevation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.